![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00242554 |
To assess the effects of i.v. zoledronic acid 4 mg with respect to safety and tolerability
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: Zoledronic acid |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Open-Label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-related inclusion / exclusion criteria may apply
Study ID Numbers: | CZOL446EMX01 |
Study First Received: | October 9, 2005 |
Last Updated: | August 16, 2006 |
ClinicalTrials.gov Identifier: | NCT00242554 History of Changes |
Health Authority: | Mexico: Ethics Committee |
Prostate Cancer Bone Metastases Zoledronic acid |
Diphosphonates Zoledronic acid Prostatic Diseases Genital Neoplasms, Male Neoplasm Metastasis |
Bone Density Conservation Agents Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Zoledronic acid Genital Neoplasms, Male Prostatic Diseases Physiological Effects of Drugs Urogenital Neoplasms Bone Density Conservation Agents Genital Diseases, Male Pharmacologic Actions |
Neoplastic Processes Neoplasms Pathologic Processes Neoplasms by Site Diphosphonates Neoplasm Metastasis Prostatic Neoplasms |